Grifols (GIFLF) Change in Account Payables (2010 - 2022)
Grifols' (GIFLF) quarterly Change in Account Payables came in at $129.1 million in Q4 2022, up 602.21% quarter-over-quarter from -$25.7 million in Q1 2020.
Analysis
Grifols (GIFLF) Change in Account Payables (2010 - 2022) Analysis & Trends
Grifols (GIFLF) has reported Change in Account Payables for 12 consecutive years, with $129.1 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Change in Account Payables changed N/A year-over-year to $129.1 million; the trailing twelve-month figure through Dec 2022 stood at -$30.6 million (changed N/A YoY), and the FY2025 full-year result was $106.2 million, up 242.71% from the prior year.
- Change in Account Payables advanced to $129.1 million in Q4 2022 per GIFLF's latest filing, from -$25.7 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $129.1 million in Q4 2022 and bottomed at -$78.2 million in Q4 2019.
- Historically, Change in Account Payables has averaged -$5.9 million across 4 years, with a median of -$22.7 million in 2018.
- The sharpest annual moves came in 2019 and 2020: Change in Account Payables sank 1957.3% in 2019, then soared 53.91% in 2020.
- Over 4 years, Change in Account Payables stood at $4.2 million in 2018, then tumbled by 1957.3% to -$78.2 million in 2019, then soared by 67.14% to -$25.7 million in 2020, then jumped by 602.21% to $129.1 million in 2022.
- According to Business Quant data, Change in Account Payables over the past three periods registered $129.1 million, -$25.7 million, and -$78.2 million for Q4 2022, Q1 2020, and Q4 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 7.11 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 129.08 Mn |
| Mar 31, 2020 | -25.70 Mn |
| Dec 31, 2019 | -78.22 Mn |
| Mar 31, 2019 | -55.77 Mn |
| Dec 31, 2018 | 4.21 Mn |
| Jun 30, 2018 | -22.71 Mn |
| Mar 31, 2018 | 8.02 Mn |
| Dec 31, 2017 | 48.35 Mn |
| Jun 30, 2017 | 34.54 Mn |
| Mar 31, 2017 | 19.09 Mn |
| Dec 31, 2016 | 81.49 Mn |
| Sep 30, 2016 | -70.38 Mn |
| Dec 31, 2015 | -282.65 Mn |
| Sep 30, 2015 | 21.41 Mn |
| Jun 30, 2015 | 337.12 Mn |
| Mar 31, 2015 | -182.68 Mn |
| Dec 31, 2014 | 94.13 Mn |
| Sep 30, 2014 | 122.80 Mn |
| Jun 30, 2014 | -70.78 Mn |
| Mar 31, 2014 | 70.80 Mn |